All In Biotech

Free tool

FAERS Monitor: Natroba

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022408 or its brand name (Natroba, Spinosad). Reports on generic versions are filed under their own applications.

Reports

47

Serious

13

28% of reports

Hospitalization

2

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective15
  • pruritus7
  • alopecia5
  • rash4
  • condition aggravated3
  • erythema3
  • abdominal pain upper2
  • burning sensation2
  • death2
  • headache2
  • lice infestation2
  • paraesthesia2
  • product quality issue2
  • seizure2
  • sleep disorder2

Reports by year received

View as table
YearReports
20113
20128
20131
20142
20161
20173
20182
20193
20204
20212
20221
20233
20243
20257
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,112 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lice infestation24307.31102.34,797
burning sensation212.83.312
sleep disorder212.73.311
alopeciaSignal511.45.038
pruritusSignal78.24.138
seizure27.72.06
product quality issue26.61.75
erythemaSignal36.52.29
paraesthesia25.71.54
drug ineffectiveSignal155.13.448
condition aggravatedSignal34.41.55
abdominal pain upper24.31.12
rashSignal44.11.67
headache21.40.40
death21.00.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.